1. Recent Articles

    1. The role of surgery in delayed local treatment for INSS 4 neuroblastoma.

      The role of surgery in delayed local treatment for INSS 4 neuroblastoma.

      Pediatr Int. 2017 Jun 23;:

      Authors: Uehara S, Yoneda A, Oue T, Nakahata K, Zenitani M, Miyamura T, Hashii Y, Fukuzawa M, Okuyama H

      Abstract PURPOSE: The aim of the present study was to compare the efficacy, complications and outcomes of the following two different surgical strategies, in patients receiving delayed local treatment for INSS 4 neuroblastoma (NB): complete resection (CR; period A), and gross total resection (GTR)/subtotal resection (STR) with local irradiation (period B). METHODS: We retrospectively analyzed 17 patients with INSS 4 neuroblastoma (NB) who ...

      Read Full Article
      Mentions: Treatment Surgery
    2. Neonates with cancer and causes of death; lessons from 615 cases in the SEER databases.

      Neonates with cancer and causes of death; lessons from 615 cases in the SEER databases.

      Cancer Med. 2017 Jun 22;:

      Authors: Alfaar AS, Hassan WM, Bakry MS, Qaddoumi I

      Abstract Neonatal tumors are rare with no standard treatment approaches to these diseases, and the patients experience poor outcomes. Our aim was to determine the distribution of cancers affecting neonates and compare survival between these cancers and older children.

      Read Full Article
      Mentions: Treatment
    3. Neuroblast differentiation during development and in neuroblastoma requires KIF1Bβ-mediated transport of TRKA.

      Neuroblast differentiation during development and in neuroblastoma requires KIF1Bβ-mediated transport of TRKA.

      Genes Dev. 2017 May 15;31(10):1036-1053

      Authors: Fell SM, Li S, Wallis K, Kock A, Surova O, Rraklli V, Höfig CS, Li W, Mittag J, Henriksson MA, Kenchappa RS, Holmberg J, Kogner P, Schlisio S

      Read Full Article
      Mentions: MYCN
    4. MRI without contrast agents? Yes, with sugar!

      MRI without contrast agents? Yes, with sugar!

      ( German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) ) Scientists from the German Cancer Research Center (DKFZ), in collaboration with colleagues from Heidelberg University Hospital, have been able to visualize brain cancer using a novel MRI method. They use a simple sugar solution instead of conventional contrast agents, which can have side effects in the body.

      Read Full Article
      Mentions: Side Effects
    5. New biomarker assay detects neuroblastoma with greater sensitivity

      Investigators have developed and tested a new biomarker assay for quantifying disease and detecting the presence of neuroblastoma even when standard evaluations yield negative results for the disease. Researchers provide the first systematic comparison of standard imaging evaluations versus the new assay that screens for five different neuroblastoma-associated genes and determine that the new assay improves disease assessment and provides prediction of disease progression.

      Read Full Article
      Mentions: NANT Imaging MIBG
    6. New biomarker assay detects neuroblastoma with greater sensitivity

      New biomarker assay detects neuroblastoma with greater sensitivity

      ( Children's Hospital Los Angeles ) Investigators at The Saban Research Institute of Children's Hospital Los Angeles have developed and tested a new biomarker assay for quantifying disease and detecting the presence of neuroblastoma even when standard evaluations yield negative results for the disease.

      Read Full Article
      Mentions: NANT MIBG
    7. New research points to potential targeted treatments of neuroblastoma tumours

      New research points to potential targeted treatments of neuroblastoma tumours

      Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research by the University of Chicago Medicine.

      The findings lay the groundwork for developing more targeted treatments for...

      Read Full Article
      Mentions: MYCN
    8. Potential for more targeted treatments of neuroblastoma tumors

      Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research. The findings lay the groundwork for developing more targeted treatments for particularly deadly variations of the cancer.

      Read Full Article
      Mentions: MYCN
    9. Altered erythropoiesis and decreased number of erythrocytes in children with neuroblastoma.

      Altered erythropoiesis and decreased number of erythrocytes in children with neuroblastoma.

      Oncotarget. 2017 May 30;:

      Authors: Morandi F, Barco S, Stigliani S, Croce M, Persico L, Lagazio C, Scuderi F, Belli ML, Montera M, Cangemi G, Pozzi S, Rigo V, Scaruffi P, Amoroso L, Erminio G, Pistoia V, Ferrini S, Corrias MV

      Read Full Article
    10. New research points to potential for more targeted treatments of neuroblastoma tumors

      New research points to potential for more targeted treatments of neuroblastoma tumors

      ( University of Chicago Medical Center ) Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research by the University of Chicago Medicine. The findings lay the groundwork for developing more targeted treatments for particularly deadly variations of the cancer.

      Read Full Article
      Mentions: MYCN
    11. NK Cell-derived Exosomes From NK Cells Previously Exposed to Neuroblastoma Cells Augment the Antitumor Activity of Cytokine-activated NK Cells.

      NK Cell-derived Exosomes From NK Cells Previously Exposed to Neuroblastoma Cells Augment the Antitumor Activity of Cytokine-activated NK Cells.

      J Immunother. 2017 Jun 15;:

      Authors: Shoae-Hassani A, Hamidieh AA, Behfar M, Mohseni R, Mortazavi-Tabatabaei SA, Asgharzadeh S

      Read Full Article
      Mentions: NK Cells
    12. See all articles
  2. Comments

  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Topics in the News

    1. (8 articles) MYCN
    2. (6 articles) Treatment
    3. (6 articles) MIBG
    4. (3 articles) ASCO
    5. (3 articles) PD-1
  3. Recent Quotes

    1. We wanted to remove an important barrier in using B cells as an antigen-presenting cell population, helping them complement or replace dendritic cells.
      By Gregory Szeto
    2. The antigen-presenting capabilities of B cells have often been underestimated, but they are being increasingly appreciated for their practical advantages in therapies.
      By Gail Bishop
    3. Our dream is to spawn out a whole class of therapies which involve taking out your own cells, telling them what to do, and putting them back into your body to fight your disease, whatever that may be.
      By Armon Sharei
    4. We envision a future system, if we can take advantage of its microfluidic nature, as a bedside or field-deployable device.
      By Armon Sharei
    5. Down the road, you could potentially get enough cells from just a normal syringe-based blood draw, run it through a bedside device that has the antigen you want to vaccinate against, and then you'd have the vaccine.
      By Gregory Szeto
    6. The problem is that unlike blood, a skin sample or even a tissue biopsy, you can't take a piece of a patient's neural system. It runs like complex wiring throughout the body and portions cannot be sampled for study.
      By Mick Bhatia
    7. Now we can take easy to obtain blood samples, and make the main cell types of neurological systems - the central nervous system and the peripheral nervous system - in a dish that is specialized for each patient.
      By Mick Bhatia
    8. If I was a patient and I was feeling pain or experiencing neuropathy, the prized pain drug for me would target the peripheral nervous system neurons, but do nothing to the central nervous system, thus avoiding non-addictive drug side effects.
      By Mick Bhatia
    9. This bench to bedside research is very exciting and will have a major impact on the management of neurological diseases, particularly neuropathic pain.
      By Akbar Panju
    10. The dBET1 and the dFKBP12 compounds are presently in a late stage of lead optimization for therapeutic development in both cancer and non-malignant diseases, Composition-of-matter and method-of-use patent applications have been filed on these and other additional targeted agents, as well as on the chemistry platform.
      By Prem Das